Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate

Wetter, Axel; Lipponer, Christine; Nensa, Felix; Beiderwellen, Karsten; Olbricht, Th.; Rübben, H.; Bockisch, Andreas; Schlosser, Thomas; Heusner, Till A.; Lauenstein, Thomas C.

doi:10.1097/rli.0b013e318282c654

Cited by 61 publications

(45 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, combined PET/MR imaging could facilitate the use of targeted focal therapy and the determination of its efficacy (Fig. 3) (24). Another interesting prospect is the potential utility of dual-modality imaging agents in this clinical setting (25).…”

Section: Potential Opportunities With Pet/mr Imagingmentioning

confidence: 99%

Molecular Imaging of Prostate Cancer with PET

Jadvar¹

2013

J Nucl Med

View full text Add to dashboard Cite

Molecular imaging is paving the way for precision and personalized medicine. In view of the significant biologic and clinical heterogeneity of prostate cancer, molecular imaging is expected to play an important role in the evaluation of this prevalent disease. The natural history of prostate cancer spans from an indolent localized process to biochemical relapse after radical treatment with curative intent to a lethal castrate-resistant metastatic disease. The ongoing unraveling of the complex tumor biology of prostate cancer uniquely positions molecular imaging with PET to contribute significantly to every clinical phase of prostate cancer evaluation. The purpose of this article was to provide a concise review of the current state of affairs and potential future developments in the diagnostic utility of PET in prostate cancer.

show abstract

Section: Potential Opportunities With Pet/mr Imagingmentioning

confidence: 99%

Molecular Imaging of Prostate Cancer with PET

Jadvar¹

2013

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…The first reports on PET/MRI in oncologic imaging focused on the feasibility of whole-body PET/MRI for staging purposes in comparison to the clinical standard of PET/CT and found promising results (13)(14)(15)(16)). …”

Section: Oncologymentioning

confidence: 99%

“…Regarding primary prostate cancer, PET/MRI allows for precise mapping of PET positive lesions and is therefore clearly advantageous over PET/CT, where an anatomical allocation is difficult due to the reduced tissue contrast of the prostate in CT. In particular, regions of benign prostatic hyperplasia, which can show a pronounced choline uptake, can be accurately identified with PET/MRI and distinguished from tumor-suspicious lesions (15). Including the PET component in multiparametric MRI of the prostate by means of integrated PET/ MRI might therefore be a future option regarding primary prostate cancer detection and tumor staging.…”

Section: A B Cmentioning

confidence: 99%

“…Jones and Budinger (12) even proposed that the combination of ionizing radiation-free MRI with short-lived PET nuclides such as 15 O or 11 C could allow for integrated PET/ MRI at acceptable absorbed doses of radiation, creating a potential for the imaging of the human fetus in vivo. Hirsch et al (11) reported their initial experience after 21 PET/MRI studies in 15 children with multifocal malignant diseases.…”

Section: Pediatricmentioning

confidence: 99%

See 1 more Smart Citation

Clinical applications of PET/MRI: current status and future perspectives

Nensa

Beiderwellen²,

Heusch³

et al. 2014

Diagn Interv Radiol

Self Cite

112

View full text Add to dashboard Cite

Fully integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) scanners have been available for a few years. Since then, the number of scanner installations and published studies have been growing. While feasibility of integrated PET/MRI has been demonstrated for many clinical and preclinical imaging applications, now those applications where PET/MRI provides a clear benefit in comparison to the established reference standards need to be identified. The current data show that those particular applications demanding multiparametric imaging capabilities, high soft tissue contrast and/or lower radiation dose seem to benefit from this novel hybrid modality. Promising results have been obtained in whole-body cancer staging in non-small cell lung cancer and multiparametric tumor imaging. Furthermore, integrated PET/MRI appears to have added value in oncologic applications requiring high soft tissue contrast such as assessment of liver metastases of neuroendocrine tumors or prostate cancer imaging. Potential benefit of integrated PET/ MRI has also been demonstrated for cardiac (i.e., myocardial viability, cardiac sarcoidosis) and brain (i.e., glioma grading, Alzheimer's disease) imaging, where MRI is the predominant modality. The lower radiation dose compared to PET/computed tomography will be particularly valuable in the imaging of young patients with potentially curable diseases. However, further clinical studies and technical innovation on scanner hard-and software are needed. Also, agreements on adequate refunding of PET/MRI examinations need to be reached. Finally, the translation of new PET tracers from preclinical evaluation into clinical applications is expected to foster the entire field of hybrid PET imaging, including PET/MRI. B oth positron emission tomography (PET) and magnetic resonance imaging (MRI) are well-established imaging modalities that have been clinically available for more than 30 years. However, the combination of PET and computed tomography (CT) into PET/CT has heralded a new era of hybrid imaging driven by the rapid ascend of PET/CT and the decline of stand-alone PET. The integration of PET and CT into a hybrid system provided added value that exceeds the sum of its parts, in particular fast and accurate attenuation correction and the combination of anatomical and molecular information.Inspired by the vast success of PET/CT, the combination of PET and MRI was an obvious goal. Therefore initial solutions comprised the software based co-registration and post-hoc fusion (1) of independently acquired PET and MRI data, as well as shared tabletop sequential PET and MRI acquisition (2, 3). While the integration of PET and CT into a hybrid system was challenging but technically feasible, the integration of PET and MRI was considered extremely demanding, if not impossible. Two main technical challenges that had to be solved: in the first place development of a PET insert that is compatible to high magnetic field strengths normally used in MRI, and vice versa development ...

show abstract

“…Integrated 18 F-FDG PET/MR imaging provides a combination of superior morphologic tumor characterization and visualization of tumor metabolism (11)(12)(13)(14) and, thus, might hold great potential in the diagnosis and follow-up of cardiac tumors.…”

mentioning

confidence: 99%

Integrated ¹⁸F-FDG PET/MR Imaging in the Assessment of Cardiac Masses: A Pilot Study

et al. 2014

Self Cite

View full text Add to dashboard Cite

The objective of the present study was to evaluate whether integrated 18 F-FDG PET/MR imaging could improve the diagnostic workup in patients with cardiac masses. Methods: Twenty patients were prospectively assessed using integrated cardiac 18 F-FDG PET/MR imaging: 16 patients with cardiac masses of unknown identity and 4 patients with cardiac sarcoma after surgical therapy. All scans were obtained on an integrated 3-T PET/MR device. The MR protocol consisted of half Fourier acquisition single-shot turbo spin-echo sequence, cine, and T2-weighted images as well as T1-weighted images before and after injection of gadobutrol. PET data were acquired simultaneously with the MR scan after injection of 199 ± 58 MBq of 18 F-FDG. Patients were prepared with a high-fat, lowcarbohydrate diet in a period of 24 h before the examination, and 50 IU/kg of unfractionated heparin were administered intravenously 15 min before 18 F-FDG injection. Results: Cardiac masses were diagnosed as follows: metastases, 3; direct tumor infiltration via pulmonary vein, 1; local relapse of primary sarcoma after surgery, 2; Burkitt lymphoma, 1; scar/patch tissue after surgery of primary sarcoma, 2; myxoma, 4; fibroelastoma, 1; caseous calcification of mitral annulus, 3; and thrombus, 3. The maximum standardized uptake value (SUV max ) in malignant lesions was significantly higher than in nonmalignant cases (13.2 ± 6.2 vs. 2.3 ± 1.2, P 5 0.0004). When a threshold of 5.2 or greater was used, SUV max was found to yield 100% sensitivity and 92% specificity for the differentiation between malignant and nonmalignant cases. T2-weighted hyperintensity and contrast enhancement both yielded 100% sensitivity but a weak specificity of 54% and 46%, respectively. Morphologic tumor features as assessed by cine MR imaging yielded 86% sensitivity and 92% specificity. Consent interpretation using all available MR features yielded 100% sensitivity and 92% specificity. A Boolean 'AND' combination of an SUV max of 5.2 or greater with consent MR image interpretation improved sensitivity and specificity to 100%. Conclusion: In selected patients, 18 F-FDG PET/MR imaging can improve the noninvasive diagnosis and follow-up of cardiac masses.

show abstract

Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate

Cited by 61 publications

References 13 publications

Molecular Imaging of Prostate Cancer with PET

Molecular Imaging of Prostate Cancer with PET

Clinical applications of PET/MRI: current status and future perspectives

Integrated ¹⁸F-FDG PET/MR Imaging in the Assessment of Cardiac Masses: A Pilot Study

Contact Info

Product

Resources

About

Simultaneous 18F Choline Positron Emission Tomography/Magnetic Resonance Imaging of the Prostate

Cited by 61 publications

References 13 publications

Molecular Imaging of Prostate Cancer with PET

Molecular Imaging of Prostate Cancer with PET

Clinical applications of PET/MRI: current status and future perspectives

Integrated 18F-FDG PET/MR Imaging in the Assessment of Cardiac Masses: A Pilot Study

Contact Info

Product

Resources

About

Integrated ¹⁸F-FDG PET/MR Imaging in the Assessment of Cardiac Masses: A Pilot Study